Apokyn (apomorphine hydrochloride) is a prescription drug used to treat certain symptoms of advanced Parkinson’s disease. Apokyn comes as a liquid solution for injection under the skin. It’s usually ...

APOKYN must be injected just under the skin and not into a vein. Patients and caregivers must receive detailed instructions in the preparation and injection of doses, with particular attention paid to ...

TruPharma and its development and commercial partner Sage have received the Food and Drug Administration’s blessing for generic apomorphine hydrochloride cartridges 30 mg/3 mL (10 mg/mL). The ...

Sage Chemical is a privately held pharmaceutical company dedicated to developing and commercializing niche pharmaceutical products. Sage has been in business since 1999, initially distributing hard-to ...

LONDON (CBS.MW) -- Mylan Laboratories said the Food and Drug Administration has approved Apokyn as a therapy for the acute, intermittent treatment of hypomobility associated with advanced Parkinson's ...

Resources freed by the sale of Apokyn® rights will be reallocated to our priority projects. Our neurology sales force in North America will now be fully committed to the commercial success of Dysport® ...

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/c8mz88/apokyn) has announced the addition of the "Apokyn (Parkinson's ...

April 29, 2004 — The U.S. Food and Drug Administration (FDA) has approved an apomorphine injection for Parkinson's disease, a pediatric indication for fluticasone propionate and salmeterol 100/50 µg ...

Credit: Getty Images. The approval is only for the drug cartridges, which are compatible for use with the Apokyn Pen, the brand name pen injector. The Food and Drug Administration (FDA) has approved ...

NEW YORK (MarketWatch) -- Mylan Laboratories said it was selling its U.S. and Canadian rights for its Apokyn Parkinson's disease treatment for $23 million in cash to Vernalis PLC. All obligations, ...